Brief: Acurx Pharmaceuticals Receives FDA Conditional Acceptance
17/08/2026 13:12
BRIEF-Acurx Pharmaceuticals Receives FDA Conditional Acceptance Aug 17 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O:
ACURX PHARMACEUTICALS RECEIVES FDA CONDITIONAL ACCEPTANCE AND USPTO TRADEMARK ALLOWANCE FOR THE COMPANY'S BRAND NAME FOR IBEZAPOLSTAT
Source text: ID:nPn41hVmza
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsBrief: Acurx Pharmaceuticals Receives FDA Conditional Acceptance
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Acurx Pharmaceuticals Q2 loss widens on higher R&D costs
Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program